EGFR and non-small cell lung carcinoma: Herein, we report a patient who was diagnosed with NSCLC at stage IVB, benefited from maintenance chemotherapy and subsequent epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) treatment after progression of chemotherapy, and has survived for more than 9 years.